Related Experiment Videos
[Heart failure: symptomatic treatment versus prognostic modification].
1Unidade de Investigação e Desenvolvimento Cardiovascular do Porto, Faculdade de Medicina do Porto, Hospital de S. João.
Summary
Heart failure treatment focuses on improving prognosis by targeting neurohormonal systems, not just symptoms. Current therapies like ACE inhibitors and beta-blockers aim to counteract these detrimental regulatory systems for better patient outcomes.
Area of Science:
- Cardiology
- Pharmacology
- Physiology
Context:
- Heart failure prognosis is linked to left ventricular dysfunction and regulatory system activation.
- Patient symptoms stem from hemodynamic and skeletal muscle issues, often not improving with symptom-relief drugs.
- Current therapeutic focus is shifting from hemodynamic improvement to influencing prognosis via neurohormonal antagonism.
Purpose:
- To explore the relationship between heart failure prognosis, left ventricular dysfunction, and regulatory system activation.
- To highlight the limitations of symptom-focused pharmacological interventions in improving heart failure prognosis.
- To identify future therapeutic challenges in antagonizing neurohormonal systems for better heart failure outcomes.
Summary:
- Heart failure prognosis depends on left ventricular dysfunction and activated neurohormonal systems, while symptoms arise from hemodynamic and muscle disturbances.
- Symptomatic relief in heart failure does not always correlate with improved prognosis due to the disconnect between symptoms and underlying disease progression.
- Antagonizing neurohormonal and regulatory systems represents the primary future challenge for improving heart failure prognosis, moving beyond purely hemodynamic management.
Impact:
- Identifies key therapeutic targets for improving heart failure prognosis beyond symptom management.
- Highlights the importance of neurohormonal antagonism in heart failure treatment strategies.
- Provides a foundation for developing novel therapies aimed at modifying the long-term course of heart failure.